Cytoprotection by inhaled carbon monoxide before cardiopulmonary bypass in preclinical models.
Although a potentially toxic gaseous molecule, carbon monoxide recently gains rising scientifically and clinical interest as its beneficial effects and mechanisms of action are defined substantially in various in vitro and in vivo experiments. Its anti-inflammatory, anti-apoptotic and anti-proliferative properties but its increasing impact concerning numerous disease models in means of protection, well describe this gas as a new and challenging therapeutic alternative. In this review, we focus on the extensively analyzed advantageous value of pre- and postconditioning with inhaled carbon monoxide in the context of lung and kidney injury, induced by the low perfusion during and after cardiopulmonary bypass. Mechanisms like the heat shock response as well as an expanded view regarding toxicity and side effects are described broadly.
Department of Anesthesiology and Critical Care Medicine, University Medical Center Freiburg, Germany. torsten.loop@uniklinik-freiburg.de
Torsten
T
Loop
Christian
C
Schlensak
Ulrich
U
Goebel
D058186:Acute Kidney Injury / Q000517:prevention & control; D055371:Acute Lung Injury / Q000517:prevention & control; D000280:Administration, Inhalation; D000818:Animals; D002248:Carbon Monoxide / Q000494:pharmacology* / Q000627:therapeutic use; D002315:Cardiopulmonary Bypass; D019610:Cytoprotection / Q000187:drug effects*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D020011:Protective Agents / Q000494:pharmacology* / Q000627:therapeutic use
D020011:Protective Agents; D002248:Carbon Monoxide